{Reference Type}: Journal Article
{Title}: SER recommendations on treatment of refractory Behçet's syndrome.
{Author}: Moriano Morales C;Graña Gil J;Brito García N;Martín Varillas JL;Calvo Del Río V;Moya Alvarado P;Narváez García FJ;Espinosa G;Díaz Del Campo Fontecha P;Guerra Rodríguez M;Mateo Arranz J;López Gómez M;Francisco Hernández FM;Trujillo MM;Dos Santos Sobrín R;Martín Sánchez JI;Maese Manzano J;Suárez Cuba J;
{Journal}: Reumatol Clin (Engl Ed)
{Volume}: 20
{Issue}: 4
{Year}: 2024 Apr 12
暂无{DOI}: 10.1016/j.reumae.2023.12.006
{Abstract}: <B>OBJECTIVE: </B>To develop multidisciplinary recommendations based on available evidence and expert consensus for the therapeutic management of patients with refractory Behçet's syndrome (BS) (difficult to treat, severe resistant, severe relapse) to conventional treatment.<BR><B>METHODS: </B>A group of experts identified clinical research questions relevant to the objective of the document. These questions were reformulated in PICO format (patient, intervention, comparison and outcome). Systematic reviews of the evidence were conducted, the quality of the evidence was evaluated following the methodology of the international working group Grading of Recommendations Assessment, Development, and Evaluation (GRADE). After that, the multidisciplinary panel formulated the specific recommendations.<BR><B>RESULTS: </B>4 PICO questions were selected regarding the efficacy and safety of systemic pharmacological treatments in patients with BS with clinical manifestations refractory to conventional therapy related to mucocutaneous and/or articular, vascular, neurological parenchymal and gastrointestinal phenotypes. A total of 7 recommendations were made, structured by question, based on the identified evidence and expert consensus.<BR><B>CONCLUSIONS: </B>The treatment of most severe clinical manifestations of BS lacks solid scientific evidence and, besides, there are no specific recommendation documents for patients with refractory disease. With the aim of providing a response to this need, here we present the first official Recommendations of the Spanish Society of Rheumatology for the management of these patients. They are devised as a tool for assistance in clinical decision making, therapeutic homogenisation and to reduce variability in the care of these patients.